138 related articles for article (PubMed ID: 17003944)
21. Age-stratified seroprevalence of measles, mumps and rubella (MMR) virus infections in Switzerland after the introduction of MMR mass vaccination.
Matter L; Germann D; Bally F; Schopfer K
Eur J Epidemiol; 1997 Jan; 13(1):61-6. PubMed ID: 9062781
[TBL] [Abstract][Full Text] [Related]
22. Seroepidemiological study of measles after the 1992 nationwide MMR revaccination program in Taiwan.
Chiu HH; Lee CY; Chih TW; Lee PI; Chang LY; Lin YJ; Hsu CM; Huang LM
J Med Virol; 1997 Jan; 51(1):32-5. PubMed ID: 8986946
[TBL] [Abstract][Full Text] [Related]
23. Efficacy of measles and rubella vaccination one year after the nationwide campaign in Shiraz, Iran.
Pourabbas B; Ziyaeyan M; Alborzi A; Mardaneh J
Int J Infect Dis; 2008 Jan; 12(1):43-6. PubMed ID: 17950020
[TBL] [Abstract][Full Text] [Related]
24. Immunogenicity of measles and rubella vaccines in Oman: a prospective clinical trial.
Kohler KA; Suleiman AJ; Robertson SE; Malankar P; Al-Khusaiby S; Helfand RF; Brown D; Bellini WJ; Sutter RW
J Infect Dis; 2003 May; 187 Suppl 1():S177-85. PubMed ID: 12721911
[TBL] [Abstract][Full Text] [Related]
25. Low mumps antibody levels induced by mumps-measles-rubella vaccinations in type 1 diabetic children.
Hiltunen M; Hyöty H; Leinikki P; Akerblom HK; Tuomilehto J; Vesikari T
Diabet Med; 1994 Dec; 11(10):942-6. PubMed ID: 7895458
[TBL] [Abstract][Full Text] [Related]
26. [The goals of the World Health Organization in the vaccinal prophylaxis of measles and rubella].
Tatochenko VK
Zh Mikrobiol Epidemiol Immunobiol; 2000; (3):51-4. PubMed ID: 10925875
[No Abstract] [Full Text] [Related]
27. Immunogenicity and reactogenicity of indigenously produced MMR vaccine.
Bhargava I; Chhaparwal BC; Phadke MA; Irani SF; Chhaparwal D; Dhorje S; Maheshwari CP
Indian Pediatr; 1995 Sep; 32(9):983-8. PubMed ID: 8935261
[TBL] [Abstract][Full Text] [Related]
28. The national measles and rubella campaign--one year on.
Commun Dis Rep CDR Wkly; 1995 Nov; 5(45):237. PubMed ID: 8541943
[No Abstract] [Full Text] [Related]
29. Decline in rates of seropositivity for measles, mumps, and rubella antibodies among previously immunized children treated for acute leukemia.
Feldman S; Andrew M; Norris M; McIntyre B; Iyer R
Clin Infect Dis; 1998 Aug; 27(2):388-90. PubMed ID: 9709893
[TBL] [Abstract][Full Text] [Related]
30. Reactogenicity and immunogenicity of a new combined measles-mumps-rubella vaccine: results of a multicentre trial. The Cooperative Group for the Study of MMR vaccines.
Crovari P; Gabutti G; Giammanco G; Dentico P; Moiraghi AR; Ponzio F; Soncini R
Vaccine; 2000 Jun; 18(25):2796-803. PubMed ID: 10812221
[TBL] [Abstract][Full Text] [Related]
31. Immunogenicity and efficacy of one dose measles-mumps-rubella (MMR) vaccine at twelve months of age as compared to monovalent measles vaccination at nine months followed by MMR revaccination at fifteen months of age.
Ceyhan M; Kanra G; Erdem G; Kanra B
Vaccine; 2001 Aug; 19(31):4473-8. PubMed ID: 11483273
[TBL] [Abstract][Full Text] [Related]
32. Immunity to measles before and after MMR booster or primary vaccination at 12 years of age in the first generation offered the 2-dose immunization programme.
Broliden K; Levén B; Arneborn M; Böttiger M
Scand J Infect Dis; 1998; 30(1):23-7. PubMed ID: 9670354
[TBL] [Abstract][Full Text] [Related]
33. Differential loss of humoral immunity against measles, mumps, rubella and varicella-zoster virus in children treated for cancer.
Bochennek K; Allwinn R; Langer R; Becker M; Keppler OT; Klingebiel T; Lehrnbecher T
Vaccine; 2014 Jun; 32(27):3357-61. PubMed ID: 24793952
[TBL] [Abstract][Full Text] [Related]
34. CHRONOVAC VOYAGEUR: A study of the immune response to yellow fever vaccine among infants previously immunized against measles.
Goujon C; Gougeon ML; Tondeur L; Poirier B; Seffer V; Desprès P; Consigny PH; Vray M;
Vaccine; 2017 Oct; 35(45):6166-6171. PubMed ID: 28958813
[TBL] [Abstract][Full Text] [Related]
35. Evaluation of nationwide supplementary immunization in Lao People's Democratic Republic: Population-based seroprevalence survey of anti-measles and anti-rubella IgG in children and adults, mathematical modelling and a stability testing of the vaccine.
Hachiya M; Miyano S; Mori Y; Vynnycky E; Keungsaneth P; Vongphrachanh P; Xeuatvongsa A; Sisouk T; Som-Oulay V; Khamphaphongphane B; Sengkeopaseuth B; Pathammavong C; Phounphenghak K; Kitamura T; Takeda M; Komase K
PLoS One; 2018; 13(3):e0194931. PubMed ID: 29596472
[TBL] [Abstract][Full Text] [Related]
36. Simultaneous control of measles and rubella by multidose vaccination schedules.
Becker NG; Rouderfer V
Math Biosci; 1996 Jan; 131(1):81-102. PubMed ID: 8589539
[TBL] [Abstract][Full Text] [Related]
37. Efficacy and safety of vaccination of marrow transplant recipients with a live attenuated measles, mumps, and rubella vaccine.
Ljungman P; Fridell E; Lönnqvist B; Bolme P; Böttiger M; Gahrton G; Linde A; Ringdén O; Wahren B
J Infect Dis; 1989 Apr; 159(4):610-5. PubMed ID: 2647859
[TBL] [Abstract][Full Text] [Related]
38. [Immune status against measles and rubella among 4 Chilean groups of different ages].
Valenzuela MT; Vega J; Leal I; Vicente M; Young V; Vera L; Fasce R; Ramírez E
Rev Med Chil; 1999 Mar; 127(3):359-65. PubMed ID: 10436723
[TBL] [Abstract][Full Text] [Related]
39. Previous exposure to measles, mumps, and rubella--but not vaccination during adolescence--correlates to the prevalence of pancreatic and thyroid autoantibodies.
Lindberg B; Ahlfors K; Carlsson A; Ericsson UB; Landin-Olsson M; Lernmark A; Ludvigsson J; Sundkvist G; Ivarsson SA
Pediatrics; 1999 Jul; 104(1):e12. PubMed ID: 10390298
[TBL] [Abstract][Full Text] [Related]
40. Vaccination status of children considered for renal transplants: missed opportunities for vaccine preventable diseases.
Genc G; Ozkaya O; Aygun C; Yakupoglu YK; Nalcacioglu H
Exp Clin Transplant; 2012 Aug; 10(4):314-8. PubMed ID: 22845763
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
